Respiratory medication used in COPD patients from seven Latin American countries : The lassyc study

Background: Limited information is available regarding medication use in COPD patients from Latin America. This study evaluated the type of medication used and the adherence to different inhaled treatments in stable COPD patients from the Latin American region. Methods: This was an observational, cross-sectional, multinational, and multicenter study in COPD patients attended by specialist doctors from seven Latin American countries. Adherence to inhaled therapy was assessed using the Test of Adherence to Inhalers (TAI) questionnaire. The type of medication was assessed as: short-acting β-agonist (SABA) or short-acting muscarinic antagonist (SAMA) only, long-acting muscarinic antagonist (LAMA), long-acting β-agonist (LABA), LABA/LAMA, inhaled corticosteroid (ICS), ICS/LABA, ICS/LAMA/LABA, or other. Results: In total, 795 patients were included (59.6% male), with a mean age of 69.5±8.7 years and post-bronchodilator FEV1of 50.0%±18.6%. The ICS/LAMA/LABA (32.9%) and ICS/LABA (27.7%) combinations were the most common medications used, followed by LABA/LAMA (11.3%), SABA or SAMA (7.9%), LABA (6.4%), LAMA (5.8%), and ICS (4.3%). The types of medication most commonly used in each Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013 category were ICS/LABA (A: 32.7%; B: 19.8%; C: 25.7%; D: 28.2%) and ICS/LAMA/LABA (A: 17.3%; B: 30.2%; C: 33%; D: 41.1%). The use of long-acting bronchodilators showed the highest adherence (good or high adherence >50%) according to the TAI questionnaire. Conclusion: COPD management in specialist practice in Latin America does not follow the current guideline recommendations and there is an overuse of ICSs in patients with COPD from this region. Treatment regimens including the use of long-acting bronchodilators are associated with the highest adherence. © 2018 Casas et al.

• Fecha de publicación: 2018
• Institución: Universidad del Rosario
• Repositorio: Repositorio EdocUR - U. Rosario
• Idioma: eng
• OAI Identifier: oai:repository.urosario.edu.co:10336/20328
• Acceso en línea: https://repository.urosario.edu.co/handle/10336/20328
• Palabra clave: Beta Adrenergic Receptor Stimulating Agent; Corticosteroid; Combination; Long Acting Drug; Muscarinic Receptor Blocking Agent; Respiratory Tract Agent; Short Acting Drug; Beta 2 Adrenergic Receptor Stimulating Agent; Bronchodilating Agent; Corticosteroid; Muscarinic Receptor Blocking Agent; Aged; Chronic Obstructive Lung Disease; Combination Drug Therapy; Cross-Sectional Study; Disease Classification; Drug Use; Forced Expiratory Volume; Global Initiative For Chronic Obstructive Lung Disease; Human; Maintenance Therapy; Major Clinical Study; Male; Medication Compliance; Monotherapy; Observational Study; Patient Compliance; Questionnaire; South And Central America; Test Of Adherence To Inhalers Questionnaire; Chronic Obstructive Lung Disease; Clinical Practice; Clinical Trial; Drug Effect; Drug Utilization Review; Health Care Disparity; Health Care Survey; Inhalational Drug Administration; Lung; Medication Compliance; Medication Overuse; Multicenter Study; Nebulizer; Pathophysiology; Prescription; Treatment Outcome; Adrenal Cortex Hormones; Adrenergic Beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Cross-Sectional Studies; Drug Prescriptions; Drug Therapy; Drug Utilization Review; Health Care Surveys; Healthcare Disparities; Latin America; Lung; Male; Medication Adherence; Muscarinic Antagonists; Nebulizers And Vaporizers; Prescription Drug Overuse; Treatment Outcome; Corticosteroides; Agente estimulante beta receptor adrenérgico; Medicamentos de acción prolongada; El bloqueo de los receptores muscarínicos agente; Farmacología & terapéutica; Corticosteroid; Long Acting Drug; Muscarinic Receptor Blocking Agent; Adult; Article; Female; Female; Humans; Inhalation; Physicians; Chronic Obstructive; Administration; Practice Patterns; Pulmonary Disease; Corticosteroides; Medicamentos de efecto retardado; Enfermedad pulmonar obstructiva crónica
• License: Abierto (Texto Completo)